Cancer Genetics Inc. (CGIX) Sees Large Volume Increase
Cancer Genetics Inc. (NASDAQ:CGIX) saw unusually-high trading volume on Wednesday . Approximately 260,909 shares traded hands during mid-day trading, an increase of 214% from the previous session’s volume of 82,986 shares.The stock last traded at $2.08 and had previously closed at $2.05.
Separately, Zacks Investment Research downgraded shares of Cancer Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th.
The stock’s market capitalization is $28.26 million. The firm’s 50-day moving average is $2.04 and its 200 day moving average is $2.34.
Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Tuesday, May 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The firm earned $6.10 million during the quarter, compared to analyst estimates of $6.95 million. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share. Analysts anticipate that Cancer Genetics Inc. will post ($1.26) EPS for the current fiscal year.
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.